🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Multi-Omics-Based Novel Thrombosis and Bleeding Markers and Risk Model for CHD

Recruitingn/aAges 18 Years - anyAllXueyan Zhao
NCT07523880 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Patients with coronary heart disease who take dual antiplatelet therapy face two serious risks: thrombosis and major bleeding. This study aims to develop better ways to predict these risks and guide personalized treatment. The investigators will use a large, long-term follow-up study of Chinese patients with coronary heart disease. This research plans to discover new biomarkers related to clot and bleeding risk. The study will combine information from proteins, metabolites, sugars attached to proteins, genes, and medical images. Using machine learning methods, the investigators will identify the most important markers and test them in the patient group of this study. The investigators will then build new risk prediction models that include these new markers together with traditional risk scores (such as GRACE, PARIS, and Precise-DAPT). This study will check whether these new models are

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Age ≥ 18 years. 2. Hospitalized due to symptoms or objective evidence of coronary heart disease and planned for long-term antithrombotic therapy. 3. Diagnosis of acute coronary syndrome or stable coronary heart disease undergoing percutaneous coronary intervention (PCI), with clinical stability meeting discharge criteria after treatment. 4. For patients from the existing cohort: minimum 2 years of follow-up with complete clinical data and blood specimens available; approval for use of these data and specimens has been obtained, with a waiver of re-consent. For newly enrolled patients: voluntary written informed consent provided by the patient or legal representative, agreement to provide blood samples, and acceptance of follow-up procedures. Exclusion Criteria: For patients from the existing cohort: 1. Severe missing or erroneous baseline or clinical data that cannot be corrected by source verification. 2. No available blood specimen, or specimen that does not meet testing requirements. For newly enrolled patients: 1. Presence of serious comorbid conditions with life expectancy ≤ 6 months. 2. Conditions that significantly affect study compliance or the ability to complete follow-up. 3. Contraindications to blood sampling.
💊

What it tests

  • Not listed
📍

Where

3 sites
Fuwai Central China Cardiovascular Hospital
Zhengzhou, China
General Hospital of Northern Theater Command of Chinese People's Liberation Army
Shenyang, China
Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy